NASDAQ:DRRX DURECT (DRRX) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free DRRX Stock Alerts $1.30 +0.04 (+3.17%) (As of 05/24/2024 ET) Add Compare Share Share Today's Range$1.22▼$1.3050-Day Range$0.77▼$1.3552-Week Range$0.47▼$6.74Volume76,863 shsAverage Volume228,868 shsMarket Capitalization$40.35 millionP/E RatioN/ADividend YieldN/APrice Target$27.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get DURECT alerts: Email Address DURECT MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.60 Rating ScoreUpside/Downside2,015.4% Upside$27.50 Price TargetShort InterestBearish3.24% of Float Sold ShortDividend StrengthN/ASustainability-1.19Upright™ Environmental ScoreNews Sentiment0.32Based on 8 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.85) to ($0.73) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.32 out of 5 starsMedical Sector299th out of 923 stocksPharmaceutical Preparations Industry134th out of 429 stocks 3.3 Analyst's Opinion Consensus RatingDURECT has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageDURECT has only been the subject of 2 research reports in the past 90 days.Read more about DURECT's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.24% of the float of DURECT has been sold short.Short Interest Ratio / Days to CoverDURECT has a short interest ratio ("days to cover") of 6.Change versus previous monthShort interest in DURECT has recently increased by 1.77%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldDURECT does not currently pay a dividend.Dividend GrowthDURECT does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreDURECT has received a 67.95% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physiological diseases " and "Clinical research services for substance abuse disorders " products. See details.Environmental SustainabilityThe Environmental Impact score for DURECT is -1.19. Previous Next 1.8 News and Social Media Coverage News SentimentDURECT has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.81 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for DURECT this week, compared to 1 article on an average week.Search InterestOnly 10 people have searched for DRRX on MarketBeat in the last 30 days. This is a decrease of -23% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added DURECT to their MarketBeat watchlist in the last 30 days. This is a decrease of -83% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, DURECT insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.30% of the stock of DURECT is held by insiders.Percentage Held by InstitutionsOnly 28.03% of the stock of DURECT is held by institutions.Read more about DURECT's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for DURECT are expected to grow in the coming year, from ($0.85) to ($0.73) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DURECT is -1.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of DURECT is -1.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDURECT has a P/B Ratio of 4.81. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about DURECT's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About DURECT Stock (NASDAQ:DRRX)DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.Read More DRRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DRRX Stock News HeadlinesMay 23 at 4:38 AM | americanbankingnews.comDURECT (NASDAQ:DRRX) Earns Neutral Rating from HC WainwrightMay 22, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Guardant Health (GH), Durect (DRRX)May 22, 2024 | americanbankingnews.comDURECT (NASDAQ:DRRX) Rating Increased to Hold at StockNews.comMay 21, 2024 | msn.comDURECT gets FDA breakthrough therapy status for larsucosterolMay 21, 2024 | prnewswire.comDURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated HepatitisMay 21, 2024 | americanbankingnews.comDURECT Co. (NASDAQ:DRRX) Receives Average Recommendation of "Moderate Buy" from BrokeragesMay 19, 2024 | americanbankingnews.comDURECT (NASDAQ:DRRX) Given Neutral Rating at HC WainwrightMay 17, 2024 | americanbankingnews.comResearch Analysts Offer Predictions for DURECT Co.'s FY2024 Earnings (NASDAQ:DRRX)May 17, 2024 | americanbankingnews.comQ2 2024 EPS Estimates for DURECT Co. Lifted by Analyst (NASDAQ:DRRX)May 16, 2024 | americanbankingnews.comBrokers Set Expectations for DURECT Co.'s Q2 2024 Earnings (NASDAQ:DRRX)May 14, 2024 | msn.comDURECT Corporation (NASDAQ:DRRX) Q1 2024 Earnings Call TranscriptMay 14, 2024 | finance.yahoo.comDurect Corp (DRRX) Q1 2024 Earnings Call Transcript Highlights: Navigating Financial Challenges ...May 13, 2024 | prnewswire.comDURECT Corporation Reports First Quarter 2024 Financial Results and Business UpdateMay 12, 2024 | msn.comDURECT Q1 2024 Earnings PreviewMay 7, 2024 | prnewswire.comDURECT Corporation to Announce First Quarter 2024 Financial Results and Provide a Business UpdateApril 30, 2024 | prnewswire.comDURECT Corporation Announces Late-Breaking Oral Presentation at the EASL Congress 2024 to Discuss AHFIRM Phase 2b Data in Alcohol-Associated HepatitisApril 1, 2024 | finance.yahoo.comDURECT Corporation (NASDAQ:DRRX) Q4 2023 Earnings Call TranscriptMarch 27, 2024 | benzinga.comDurect: Q4 Earnings InsightsMarch 27, 2024 | markets.businessinsider.comDURECT Corp. Q4 Loss decreases, beats estimatesMarch 27, 2024 | finance.yahoo.comDURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 27, 2024 | msn.comOptions Volatility and Implied Earnings Moves Today, March 27, 2024March 27, 2024 | msn.comDURECT Q4 2023 Earnings PreviewMarch 20, 2024 | finance.yahoo.comDURECT Corporation to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide a Business UpdateMarch 20, 2024 | prnewswire.comDURECT Corporation to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide a Business UpdateMarch 16, 2024 | finance.yahoo.comDRRX Apr 2024 5.000 callSee More Headlines Receive DRRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DURECT and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/27/2024Today5/26/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:DRRX CUSIPN/A CIK1082038 Webwww.durect.com Phone(408) 777-1417Fax408-777-3577Employees58Year FoundedN/APrice Target and Rating Average Stock Price Target$27.50 High Stock Price Target$41.00 Low Stock Price Target$5.00 Potential Upside/Downside+2,015.4%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.95) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-27,620,000.00 Net Margins-279.77% Pretax Margin-279.77% Return on Equity-328.25% Return on Assets-76.36% Debt Debt-to-Equity RatioN/A Current Ratio1.05 Quick Ratio0.96 Sales & Book Value Annual Sales$8.55 million Price / Sales4.72 Cash FlowN/A Price / Cash FlowN/A Book Value$0.27 per share Price / Book4.81Miscellaneous Outstanding Shares31,040,000Free Float29,704,000Market Cap$40.35 million OptionableOptionable Beta0.94 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. James E. Brown D.V.M. (Age 67)Co-Founder, CEO, President & Director Comp: $633.46kMr. Timothy M. Papp M.B.A. (Age 48)CFO & Secretary Comp: $427.62kDr. Norman L. Sussman M.D. (Age 71)Chief Medical Officer Comp: $471.71kMs. Judy R. Joice (Age 67)Senior Vice President of Operations & Corporate Quality Assurance Comp: $451.82kDr. WeiQi Lin M.D.Ph.D., Executive VP of Research & Development and Principal ScientistMr. Keith L. Lui M.B.A.Senior Vice President of Business Development, Commercial & Medical AffairsMs. Jian Li M.B.A. (Age 54)Senior VP of Finance, Corporate Controller & Secretary Comp: $297.08kDr. Su Il Yum Ph.D. (Age 85)Executive Officer Comp: $331.74kMore ExecutivesKey CompetitorsEyenoviaNASDAQ:EYENFortress BiotechNASDAQ:FBIOJaguar HealthNASDAQ:JAGXVYNE TherapeuticsNASDAQ:VYNECara TherapeuticsNASDAQ:CARAView All CompetitorsInstitutional OwnershipGagnon Securities LLCBought 21,425 shares on 5/14/2024Ownership: 1.225%Richmond Brothers Inc.Bought 250,050 shares on 5/10/2024Ownership: 2.476%Tocqueville Asset Management L.P.Bought 25,000 shares on 5/10/2024Ownership: 0.826%View All Institutional Transactions DRRX Stock Analysis - Frequently Asked Questions Should I buy or sell DURECT stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DURECT in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" DRRX shares. View DRRX analyst ratings or view top-rated stocks. What is DURECT's stock price target for 2024? 5 analysts have issued 1-year price targets for DURECT's shares. Their DRRX share price targets range from $5.00 to $41.00. On average, they expect the company's share price to reach $27.50 in the next year. This suggests a possible upside of 2,015.4% from the stock's current price. View analysts price targets for DRRX or view top-rated stocks among Wall Street analysts. How have DRRX shares performed in 2024? DURECT's stock was trading at $0.59 on January 1st, 2024. Since then, DRRX shares have increased by 120.3% and is now trading at $1.30. View the best growth stocks for 2024 here. When is DURECT's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024. View our DRRX earnings forecast. How were DURECT's earnings last quarter? DURECT Co. (NASDAQ:DRRX) released its quarterly earnings results on Wednesday, March, 27th. The specialty pharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.09. The specialty pharmaceutical company earned $2.67 million during the quarter, compared to analysts' expectations of $2.70 million. DURECT had a negative net margin of 279.77% and a negative trailing twelve-month return on equity of 328.25%. When did DURECT's stock split? Shares of DURECT reverse split before market open on Tuesday, December 6th 2022. The 1-10 reverse split was announced on Tuesday, December 6th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, December 6th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of DURECT own? Based on aggregate information from My MarketBeat watchlists, some companies that other DURECT investors own include Geron (GERN), Catalyst Pharmaceuticals (CPRX), VBI Vaccines (VBIV), MannKind (MNKD), Novavax (NVAX), Cassava Sciences (SAVA), Amarin (AMRN), Matinas BioPharma (MTNB), Inovio Pharmaceuticals (INO) and Verastem (VSTM). Who are DURECT's major shareholders? DURECT's stock is owned by many different institutional and retail investors. Top institutional shareholders include Richmond Brothers Inc. (2.48%), Gagnon Securities LLC (1.22%), Tocqueville Asset Management L.P. (0.83%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Gail J Maderis, Gail M Farfel, Judith J Robertson, Mohammad Azab and Simon X Benito. View institutional ownership trends. How do I buy shares of DURECT? Shares of DRRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:DRRX) was last updated on 5/26/2024 by MarketBeat.com Staff From Our Partners[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaWARNING about the death of the U.S. dollar…Colonial MetalsClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsBuy this small stock before coming AI Tidal WaveChaikin Analytics$1,500 to $9,400 in one month? (A.I. Trade List)Prosper Trading AcademyElon’s New Device is About to Shock the WorldInvestorPlaceNew Options need New Trading StrategiesNetpicksWrite this ticker symbol down…StocksToTrade Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DURECT Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.